Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich - Gilde Healthcare

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

February 29, 2024
Ede & Utrecht (the Netherlands)

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V., a Givaudan group company. With this move, NIZO widens its capabilities and secures the opportunity to develop the NIZO Food Innovation Campus.

“We are very excited about the acquisition”, says Nikolaas Vles, CEO of NIZO, “because this lactic acid process was once developed by NIZO, and it is a great example how NIZO can accelerate innovative transformation processes through the combination of science and operational excellence. The transaction further underscores the strong partnership between dsm-firmenich and NIZO”.

NIZO and dsm-firmenich have been working together for approximately 30 years. “NIZO’s strong expertise in food and health research and holistic project approach have often boosted our innovation development already. This supports our belief that NIZO is the right partner for dsm-firmenich for the supply of lactic acid and for support in future R&D projects” says Dirk Lippits, EVP Ingredient Solutions, Taste, Texture & Health.

NIZO is strategically focused on the protein transition, and recently completed a 5-million-euro investment program to upgrade NIZO’s pilot plant for the development and upscaling of plant-based and other alternative proteins. NIZO is also offering location opportunities for start-ups and scale-ups within this domain and is working intensively with public and private partners to further develop the NIZO Food Innovation Campus. The acquisition of the adjacent site opens the door to further developing these initiatives.

About NIZO
NIZO is a globally leading, private, and independent Contract Research Organization specializing in food and health innovation for over 75 years. Operating the largest open access food-grade pilot plant in Europe, we leverage the integrated power of science and technology to help our customers in transforming food and nutrition more successfully, sustainably, and faster; ultimately leading to better food and health. For more information:

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024

Gilde Healthcare company ProVerum Announces Completion of Enrollment for the ProVIDE Clinical Study for BPH and First-use of its New Flexible, Steerable Delivery System

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor's office, today announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate...
March 21, 2024

Gilde Healthcare sells RAD-x to a consortium of Swiss Life Asset Managers and Vesper Infrastructure Fund I

Gilde Healthcare’s Private Equity Fund (“Gilde Healthcare”), a specialized healthcare investor, has reached a binding agreement to sell its majority stake in RAD-x to a consortium of Swiss Life Asset Managers and Vesper Next Generation...
March 18, 2024